ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,341 to 4,360 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Alteplase Active Control Group vs Tenecteplase Treatment Group: serious adverse events115 of 736

116 of 732

-0.2 points

-4.0 to 3.5

1,468NCT04915729

A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity

Zishen Yutai Pill Group vs Placebo Group: Biochemical Pregnancy Rate232 of 734

195 of 733

5.0 points

0.4 to 9.6

1,467NCT03703700

The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET

Zishen Yutai Pill Group vs Placebo Group: Live Birth Rate171 of 734

139 of 733

4.3 points

0.2 to 8.5

1,467NCT03703700

The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET

Zishen Yutai Pill Group vs Placebo Group: Clinical Pregnancy Rate216 of 734

177 of 733

5.3 points

0.7 to 9.8

1,467NCT03703700

The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET

Zishen Yutai Pill Group vs Placebo Group: serious adverse events22 of 734

18 of 733

0.5 points

-1.2 to 2.3

1,467NCT03703700

The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET

Standard Influenza Surveillance Period vs Point-of-care Molecular Testing and Treatment of Influenza Period: Feasibility of Implementation of Point-of-care Molecular Testing and Treatment of Influenza in Shelters266 of 701

308 of 764

-2.4 points

-7.3 to 2.6

1,465NCT04141917

Test-and-treat for Influenza in Homeless Shelters

Everolimus vs Placebo: serious adverse events154 of 740

68 of 723

11.4 points

7.8 to 15.0

1,463NCT01120249

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

V419 vs Control: serious adverse events58 of 980

32 of 483

-0.7 points

-3.6 to 1.8

1,463NCT01337167

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Intervention vs Usual Care: Adherence to Medication341 of 681

250 of 782

18.1 points

13.1 to 23.0

1,463NCT02790463

Virtual Gout Clinic

Intervention vs Usual Care: sUA < 6.0 mg/dl at 1 Year204 of 681

117 of 782

15.0 points

10.7 to 19.2

1,463NCT02790463

Virtual Gout Clinic

Intervention vs Usual Care: serious adverse events1 of 681

1 of 782

0.0 points

-0.6 to 0.7

1,463NCT02790463

Virtual Gout Clinic

Caduet vs Usual Care: serious adverse events51 of 779

22 of 682

3.3 points

1.1 to 5.6

1,461NCT00407537

Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors

Short Storage vs Standard Issue: serious adverse events80 of 728

84 of 733

-0.5 points

-3.7 to 2.8

1,461NCT01977547

Age of Blood in Children in Pediatric Intensive Care Units

Trastuzumab vs Trastuzumab Emtansine: Number of Participants With AEs and SAEs Leading to Death0 of 720

1 of 740

-0.1 points

-0.8 to 0.4

1,460NCT01772472

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Trastuzumab vs Trastuzumab Emtansine: Number of Participants Who Discontinued Treatment Due to AEs15 of 720

134 of 740

-16.0 points

-19.1 to -13.1

1,460NCT01772472

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Trastuzumab vs Trastuzumab Emtansine: serious adverse events58 of 720

94 of 740

-4.6 points

-7.8 to -1.5

1,460NCT01772472

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Short Storage vs Standard Issue: Nosocomial Infection24 of 728

23 of 732

0.2 points

-1.7 to 2.0

1,460NCT01977547

Age of Blood in Children in Pediatric Intensive Care Units

Short Storage vs Standard Issue: Number of Participants With New or Progressive Multiple Organ Dysfunction Syndrome (NPMODS)147 of 728

133 of 732

2.0 points

-2.0 to 6.1

1,460NCT01977547

Age of Blood in Children in Pediatric Intensive Care Units

STS101 5.2 mg vs STS101 Placebo: serious adverse events3 of 731

0 of 729

0.4 points

-0.2 to 1.2

1,460NCT04940390

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

Depression - Immediate PGx Testing vs Depression - Delayed PGx Testing: deaths from any cause1 of 727

2 of 733

-0.1 points

-0.9 to 0.5

1,460NCT05966155

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Depression Trial)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=218"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=218

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04915729-sae",
        "title": "Alteplase Active Control Group vs Tenecteplase Treatment Group: serious adverse events",
        "summary": "115 of 736 against 116 of 732; risk difference -0.2 points, 95% interval -4.0 to 3.5; NCT04915729, A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity",
        "record": "/library/comparisons/NCT04915729-sae",
        "nct_id": "NCT04915729",
        "kind": "serious-adverse-events",
        "participants": 1468,
        "risk_difference": {
          "value": -0.0022199453551912662,
          "lower": -0.03955811188387835,
          "upper": 0.03509973161904432
        },
        "group_1": "115 of 736",
        "group_2": "116 of 732",
        "difference": "-0.2 points",
        "interval": "-4.0 to 3.5",
        "trial_title": "A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity"
      },
      {
        "id": "NCT03703700-1484b4d9",
        "title": "Zishen Yutai Pill Group vs Placebo Group: Biochemical Pregnancy Rate",
        "summary": "232 of 734 against 195 of 733; risk difference 5.0 points, 95% interval 0.4 to 9.6; NCT03703700, The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET",
        "record": "/library/comparisons/NCT03703700-1484b4d9",
        "nct_id": "NCT03703700",
        "kind": "outcome",
        "participants": 1467,
        "risk_difference": {
          "value": 0.05004628063536437,
          "lower": 0.0035505346609978894,
          "upper": 0.09624823095947349
        },
        "group_1": "232 of 734",
        "group_2": "195 of 733",
        "difference": "5.0 points",
        "interval": "0.4 to 9.6",
        "trial_title": "The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=219",
  "request_id": "OubA-VZyTRzcLby7"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?